Library Compounds Sample Clauses

Library Compounds. The Joint Steering Committee shall design Synthetic Pathways, Scaffolds and their associated Library Compounds so as not to overlap with compounds outside the scope of the Collaboration that are then in or under development for the compound collection of a Party or its Affiliates. The vote by each Party’s representatives to the Joint Steering Committee approving the designation of a Synthetic Pathway and Scaffold shall be deemed a representation by such Party that such Synthetic Pathway and Scaffold do not overlap with compounds outside the scope of the Collaboration that are then in or under development for the compound collection of such Party or its Affiliates. Upon approval, each Synthetic Pathway and Scaffold, together with representative examples and any written descriptions shall be attached and incorporated hereto as Exhibit C.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Library Compounds. Notwithstanding any other provision of this Section 2.8, Array shall not be required to disclose to Loxo the structures of any Library Compound unless such Library Compound meets those criteria required for a Compound to be an Active Compound.
Sample 1Sample 2Sample 3
Library Compounds. During the Research Program Term, Teijin shall keep CombiChem fully informed of its activities with respect to Library Compounds, including, without limitation, notification by Teijin to CombiChem of its intent to screen such Library Compound against an assay other than an assay designed to determine *** Activity or *** Receptor Activity prior to performing any such screening. Teijin shall provide CombiChem with written *** reports within *** of the end of each *** period providing such information.
Sample 1
Library Compounds. Array hereby grants to Chiroscience a non-exclusive, worldwide, paid-up right and license, without the right to sublicense, to make, have made and use the Library Compounds under all U.S. and foreign patents or other proprietary rights owned by Array to carry out Chiroscience's own internal research [ * ] under this Agreement (e.g., screening and identifying lead candidates for drug discovery and development). If Chiroscience establishes a Collaboration (including contracts for screening, production, testing and development services) with a third party, Chiroscience may disclose a Library Compound to such third party and authorize such third party to use the Library Compound as reasonably necessary for the purposes of the Collaboration (whether or not such Library Compound has been designated as an Active Compound); provided, the Collaboration must be evidenced by a written agreement that provides, among other things, the third party agrees not to provide the Library Compound to others (excepting those contractors that actually perform screening, testing, production and development services under such Collaboration and in each such event only under reasonable terms of confidentiality and restricted use) and shall use such Library Compound for the limited purpose of the Collaboration unless and until such Library Compound has been designated and maintained as an Active Compound hereunder. Chiroscience may disclose the composition of Compounds and transfer Compounds to potential Collaboration partners, in each case subject to reasonable conditions of confidentiality, without notifying Array. Notwithstanding the foregoing or any other provision of this Agreement, in no event shall Chiroscience disclose any Library Compound to ChiroTech for any reason.
Sample 1
Library Compounds. For compounds prepared in a library format, a general experimental procedure should be provided, including full experimental details, with yields, for a representative selection of library members. The synthesis protocols and selected characterized compounds must reflect the reliability and scope of the reaction sequence. Complete characterization data for compounds comprising libraries need not be reported. However, the synthesis of mixtures without member characterization does not constitute publishable research and therefore must be coupled with the identification and validation of active compounds. Reviewer evaluation of the methods utilized for establishing overall library purity will be an integral part of the manuscript review process. The following guidelines will be used. Authors must demonstrate the reliability of their reaction sequence and the purity of the compounds produced. In most instances, for the proposed chemistry to be considered successful and eligible to be judged significant, it is expected that at least 80% of the sampled members of an unpurified library will have chemical purities in excess of 80%. Of course, manuscripts describing higher standards should be considered to meet the significance criterion more readily. Sequences that meet lesser standards may be considered if their scope is clearly identified and they introduce strategies or concepts of significant novelty. Spectroscopic analyses should be provided for a random sampling of all new libraries that are not composed of composite materials. In most cases, this shall mean that 5% or 20 members of a library (whichever is greater) shall be sampled for purity and identity using appropriate methods, such as high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC- MS), gas chromatography (GC), NMR, or some combination for small molecules. Note, however, that ratios of peak areas in LC or GC analyses do not, in general, directly provide ratios of compound concentrations, and quantitative calibration must be performed in such situations. NMR against a known concentration of internal standard is an excellent technique, but significant errors can occur if tetramethylsilane (TMS) is used without consideration of its volatility. Hexamethyldisiloxane is an alternate internal standard of similar chemical shift (~0.2 ppm relative to TMS) and much lower volatility. Techniques such as HPLC, gel permeation chromatography (GPC), size-exclusion chromatogra...
Sample 1
Library Compounds. RPR [*]; provided nothing herein shall limit or otherwise affect the provisions of Section 2.11(b) or the licenses or other rights granted to RPR hereunder.
Sample 1
Library Compounds. Each Library Party shall, in consultation with Anacor and pursuant to the terms of the MTA, have the right to publish the results of its research; provided that when a Library Party desires to publish or disclose its results, the Library Party shall so notify Anacor, describing the proposed publication and Anacor shall notify the JSC of such proposed publication. Anacor shall notify the Library Party and JSC within [ * ] days of either: (i) Anacor’s decision to file a patent application, in which case Anacor may require a delay of such publication or disclosure for up to [ * ] days from the date of receipt of the publication request, to permit Anacor to pursue patent filing, or (ii) Anacor’s decision not to file a patent application in which case the Library Party shall be permitted to publish. Notwithstanding the forgoing, Anacor shall cooperate with the Foundation to make known to potential Library Parties, the existence and availability of the New Library.
Sample 1
AutoNDA by SimpleDocs
Library Compounds. In the event that Pharmacopeia determines that any Library Compound in a Focused Library or Targeted Library, which Library Compound (i) is not a Research Compound or OUT Compound, and (ii) is claimed in an Organon patent application or patent claiming a Research Compound or OUT Compound, but has a biological activity distinct from the utility claimed in such patent application or patent, or does not have the utility claimed by Organon, Pharmacopeia may notify Organon. Organon shall have a period of ninety (90) days from receipt of such notice in which to provide Pharmacopeia with evidence reasonably demonstrating that such Library Compound has the utility claimed in the patent application or patent. In the event that Organon fails to provide such evidence, Organon agrees to grant, and hereby grants to Pharmacopeia, an exclusive, worldwide, royalty-free license, with the right to grant and authorize sublicenses, under any applicable Joint Inventions and Organon Technology relating to such Library Compound to make, have made, use and sell products based thereon.
Sample 1

Related to Library Compounds

  • Combination Products If a LICENSED PRODUCT , DISCOVERY PRODUCT and/or THERAPEUTIC PROUCT is sold to any third party in combination with other products, devices, components or materials that are capable of being sold separately and are not subject to royalties hereunder (“OTHER PRODUCTS,” with the combination of products being referred to as “COMBINATION PRODUCTS” and the Other Product and Licensed Product in such Combination Product being referred to as the “COMPONENTS”), the NET SALES of such LICENSED PRODUCT, DISCOVERY PRODUCT and/or THERAPEUTIC PRODUCT included in such COMBINATION PRODUCT shall be calculated by multiplying the NET SALES of the COMBINATION PRODUCT by the fraction A/(A+B), where A is the average NET SALES price of such LICENSED PRODUCT, DISCOVERY PRODUCT and/or THERAPEUTIC PRODUCT in the relevant country, as sold separately, and B is the total average NET SALES price of all OTHER PRODUCTS in the COMBINATION PRODUCT in the relevant country, as sold separately. If, in any country, any COMPONENT is not sold separately, NET SALES for royalty determination shall be determined by the formula [C / (C+D)], where C is the aggregate average fully absorbed cost of the LICENSED PRODUCT, DISCOVERY PRODUCT and/or THERAPEUTIC PRODUCT components during the prior Royalty Period and D is the aggregate average fully absorbed cost of the other essential functional components during the prior Royalty Period, with such costs being determined in accordance with generally accepted accounting principles. To the extent that any SUBLICENSE INCOME relates to a COMBINATION PRODUCT or is otherwise calculated based on the value of one or more licenses or intellectual property rights held by the COMPANY, an AFFILIATE or SUBLICENSEE, COMPANY shall determine in good faith and report to THE PARTIES the share of such payments reasonably attributable to COMPANY’s or such AFFILIATE’s sublicense of the rights granted hereunder, based upon their relative importance and proprietary protection, which portion shall be the SUBLICENSE INCOME. THE PARTIES shall have the right to dispute such sharing determination in accordance with the dispute provisions of the AGREEMENT.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Combination Product The term “

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Develop programs 1) The Employer will develop and implement health promotion and health education programs, subject to the availability of resources. Each Appointing Authority will develop a health promotion and health education program consistent with the Minnesota Management & Budget policy. Upon request of any exclusive representative in an agency, the Appointing Authority shall jointly meet and confer with the exclusive representative(s) and may include other interested exclusive representatives. Agenda items shall include but are not limited to smoking cessation, weight loss, stress management, health education/self-care, and education on related benefits provided through the health plan administrators serving state employees.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Licensed Technology The term “Licensed Technology” shall mean the Licensed Patent Rights, Licensed Know-How and Licensed Biological Materials.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

Time is Money Join Law Insider Premium to draft better contracts faster.